2026년 4월 25일 Pubmed Today

AI and biotech

Nanotechnology-based drug delivery systems have significantly advanced modern pharmaceutics by addressing limitations associated with conventional therapies, including poor solubility, rapid systemic clearance, and nonspecific drug distribution. Among various nanocarriers, liposomes remain one of th…

PubMed ↗AAPS PharmSciTech

Tuberculosis (TB) remains a leading infectious cause of morbidity and mortality worldwide, and major diagnostic and therapeutic challenges persist despite advances in microbiologic and molecular testing. Over the past decade, molecular imaging, especially with FDG PET/CT, has transformed our underst…

PubMed ↗Seminars in nuclear medicine

Biotech

Whether a pharmacological strategy can replicate the broad improvement of human cardiometabolic health associated with brown fat (BAT) remains an active area of investigation. Here, we show that adipokine Adissp activates both glucose disposal and energy expenditure within white fat, delivering plei…

백색지방을 이용해 갈색지방의 대사 이점을 모사하는 새로운 축을 제시했다는 점에서 발견 가치가 높다. 다만 현재 근거는 동물모델 중심이어서 실제 치료 표준을 바꿀 단계는 아니며, 사람에서의 재현성과 약물화 가능성이 핵심 관전 포인트이다.

clinical 3discovery 3PubMed ↗Science advances

Senescent cells drive ageing and age-related pathologies, including cancer. Consequently, senolytics, drugs that selectively kill senescent cells, have broad therapeutic appeal. Here we report a senolytic screen of a library of 10,480 electrophilic compounds. Among 38 identified hits, we found a sub…

센escent cell의 생존 의존성을 GPX4와 ferroptosis로 연결해 새로운 제거 전략을 제시했다. 기전적 새로움은 매우 크지만, 실제 환자 치료로 이어지려면 독성, 선택성, 약물화 가능성 검증이 더 필요하다. 암 병용치료와 노화 관련 질환 양쪽에서 파급 가능성이 있어 후속 개발 가치가 높다.

discovery 4PubMed ↗Nature cell biology

Dysfunctional autophagy, a key cellular cleaning process, is a key driver of brain ageing and neurodegenerative diseases such as Alzheimer’s disease (AD). However, developing effective treatments by enhancing autophagy has been challenging, as most known compounds act through the broad mTOR pathway,…

BBB 투과성과 mTOR 비의존성이라는 제약을 동시에 겨냥한 점이 의미 있다. 다만 사람 대상 효능과 안전성은 전혀 확인되지 않아 당장 치료 표준을 바꿀 수준은 아니다. 플랫폼 자체의 확장성과 후보물질의 개발 가능성을 지켜볼 만하다.

discovery 3PubMed ↗Nature biomedical engineering